Bausch + Lomb announced today that, after engagement with potential buyers, it has no immediate plan to sell. At the end of 2024, the company issued a statement outlining its plans for a potential separation from parent company Bausch Health. The Vaughan, Ontario-based eye care company announced this in response to a request from the […]
bauschhealth
Bausch Health takes step toward separating Bausch+Lomb
Bausch Health (NYSE:BHC) announced today that it transferred shares of its Bausch + Lomb to an existing subsidiary. The Laval, Quebec–based company transferred common shares in an amount equal to approximately 38.6% of the issued and outstanding shares of Bausch + Lomb to an existing, wholly-owned, unrestricted subsidiary of the company. According to a news […]
Bausch + Lomb, Clearside Biomedical launch Xipere in U.S.
Bausch Health’s (NYSE:BHC) Bausch + Lomb and Clearside Biomedical (Nasdaq:CLSD) launched their Xipere product in the U.S. today. Clearside Biomedical designed the Xipere triamcinolone acetonide suprachoroidal injectable suspension therapy with a proposed indication for treating macular edema associated with uveitis, a form of eye inflammation. Xipere works with Clearside’s proprietary SCS Microinjector to deliver the therapy to […]
FDA accepts resubmitted NDA for Xipere from Clearside Biomedical, Bausch Health
Bausch Health (NYSE:BHC) and Clearside Biomedical (NSDQ:CLSD) announced today that the FDA accepted their resubmitted new drug application for Xipere. Clearside Biomedical designed the investigational Xipere triamcinolone acetonide suprachoroidal injectable suspension therapy with a proposed indication for the treatment of macular edema associated with uveitis. Xipere works with Clearside’s proprietary SCS Microinjector to access the back of the […]
FDA approves Bausch + Lomb dispersive ophthalmic viscosurgical device
Bausch + Lomb announced today that it received FDA approval for its ClearVisc dispersive ophthalmic viscosurgical device (OVD). Laval, Quebec–based Bausch + Lomb — the eye health business unit of Bausch Health — developed the ClearVisc OVD for use in ophthalmic surgery to aid in cataract extraction and intraocular lens (IOL) implantation through the creation […]
Clinical trials ramping up for potential coronavirus-fighting drugs
Bausch Health (NYSE:BHC) announced today that it initiated a clinical trial program in Canada to investigate the use of Virazole for treating COVID-19. With today’s announcement, Bausch joins Eli Lilly (NYSE:LLY) and Care Access Research, which both announced clinical testing of coronavirus therapies last week. Bausch’s Virazole is currently approved in the U.S. and Canada, among other […]
Clearside Biomedical inks $76m licensing deal with Bausch for Xipere
Clearside Biomedical (NSDQ:CLSD) said yesterday that it entered into a license agreement with Bausch Health Ireland (NYSE:BHC) worth up to $76 million for the Xipere device for the treatment of macular edema associated with uveitis. The agreement grants Bausch an exclusive license to develop, manufacture, distribute, promote, market and commercialize the suprachoroidal injection device. Get the full […]
Bausch Health slashes Q1 losses, raises outlook
Shares in Bausch Health (NYSE:BHC) got a bump today when the company reported a drastic reduction in first-quarter losses and raised its outlook for the rest of the year. Laval, Quebec-based Bausch reduced its losses by -98.0% to -$52.0 million, or -15¢ per share, on sales growth of 1.1% to $2.02 billion for the three months […]
Bausch closes $1.5B debt offering, note redemption
Bausch Health (NYSE:BHC) said late last week that it closed a $1.5 billion offering of senior notes with funds raised slated to support the repurchasing of previously offered senior notes. The Quebec-based company said it closed an offering of $500 million in 5.75% senior secured notes due 2027 and that its Bausch Health Americas business, […]
